Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation (VCEL) pioneers patient-specific cellular therapies for sports medicine and severe burn care through advanced regenerative science. This dedicated news hub provides investors and medical professionals with timely updates on the company’s progress in transforming treatment paradigms.
Access authoritative information on FDA approvals, clinical trial outcomes, and strategic initiatives shaping the future of cell-based therapies. Our curated collection includes:
- Quarterly earnings reports and financial disclosures
- Product launch announcements and manufacturing updates
- Research collaborations and intellectual property developments
- Regulatory milestones for novel treatment platforms
Bookmark this page for streamlined tracking of Vericel’s advancements in autologous cell therapies, including innovations in cartilage repair and burn wound management. Stay informed about developments that impact both patient care and investment considerations in the evolving biologics sector.
Kytopen, a biotechnology firm, has appointed Dr. Paul K. Wotton as the new Chair of its Board of Directors. With 35 years of experience in the biopharmaceutical industry, Dr. Wotton aims to enhance Kytopen's strategic growth by leveraging its innovative non-viral delivery technology for gene-modified cell therapies. Kytopen, co-founded by Dr. Paulo Garcia, focuses on making the process of cell therapy discovery more efficient and accessible. This leadership change is poised to align with the company’s mission to improve patient access to advanced living medicines.
Vericel Corporation (NASDAQ:VCEL) announced that President and CEO Nick Colangelo will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 10:30 a.m. ET. The presentation will focus on the company's advancements in sports medicine and severe burn care. A webcast will be available on the Investor Relations section of the Vericel website. Vericel is known for its cell therapy products, including MACI® and Epicel®, addressing cartilage defects and severe burns, respectively.
Vericel Corporation (NASDAQ:VCEL) has announced FDA approval for NexoBrid (anacaulase-bcdb), aimed at non-surgical eschar removal in adults with deep partial- and full-thickness thermal burns. The approval stems from the pivotal Phase 3 DETECT trial, which revealed a significantly higher rate of complete eschar removal compared to placebo, alongside reduced surgical intervention rates. NexoBrid is expected to launch commercially in the U.S. by Q2 2023, promising to address the unmet needs in burn care and potentially establishing itself as the new standard for treatment.
Vericel Corporation (NASDAQ:VCEL) announced its leadership's participation in two upcoming conferences. Nick Colangelo, President and CEO, will present at the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum on November 17, 2022, at 10:00 a.m. ET. Joe Mara, CFO, will follow at the Stephens Annual Investment Conference at 11:00 a.m. ET on the same day. Webcasts of the presentations will be available on Vericel's Investor Relations website. The company specializes in advanced therapies for sports medicine and severe burn care.
Vericel Corporation (NASDAQ:VCEL) reported third-quarter 2022 net product revenue of $38.6 million, an increase of 12% year-over-year. MACI net revenue rose by 30% to $31.0 million, while Epicel revenue was $7.3 million. Gross margin stood at 65%, but the company incurred a net loss of $6.6 million or $0.14 per share. Non-GAAP adjusted EBITDA was $3.3 million. The company expects full-year revenue of $164 to $166 million with MACI revenue projected at $130 to $132 million.
Vericel Corporation (NASDAQ:VCEL) will report its third-quarter 2022 financial results on November 9, 2022. The company specializes in advanced therapies for sports medicine and severe burn care, marketing two prominent cell therapy products: MACI and Epicel. A conference call will be held at 8:30 a.m. ET to discuss the results and key business highlights. Interested parties can join via a live webcast on the company's Investor Relations website. Presentation slides will also be available during the call.
Vericel Corporation (NASDAQ:VCEL) announced that Chief Financial Officer Joe Mara will present at the Ladenburg Thalmann Healthcare Conference on September 29, 2022, at 2:30 p.m. ET. This event highlights the company’s commitment to sharing insights about its advanced therapies in sports medicine and burn care. A webcast of the presentation will be accessible via the Investor Relations section of Vericel's website, ensuring that stakeholders can stay informed about the company’s developments.
Vericel Corporation (NASDAQ:VCEL) announced its participation in two upcoming investor conferences. On September 13, 2022, at 8:00 a.m. ET, President and CEO Nick Colangelo and CFO Joe Mara will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference. The following day, September 14, 2022, Joe Mara will present at the H.C. Wainwright 24th Annual Global Investment Conference at 9:00 a.m. ET. Webcasts of both events will be accessible via the Investor Relations section of Vericel's website.
Vericel Corporation (NASDAQ:VCEL) reported second-quarter 2022 net revenue of $37.0 million, a decline from $39.5 million in Q2 2021. MACI® revenue increased to $28.6 million, growing 8% year-over-year. The company posted a net loss of $9.0 million ($0.19 per share) and a 62% gross margin. Operating expenses rose to $31.9 million. Cash resources remain robust at $131 million with no debt. Guidance for total revenue is maintained at $178-$189 million for 2022, with a projected gross margin of 69%.
Data published in the Journal of Burn Care & Research highlights a retrospective study on 40 patients with significant posterior burns treated with Epicel by the Burn and Reconstructive Centers of America. Key findings include an 83% engraftment success rate after one or two applications and a 90% survival rate. The study underscores the effectiveness of standardized treatment protocols for enhancing patient outcomes in severe burns. Epicel is approved for deep dermal or full-thickness burns covering at least 30% of total body surface area.
